Search

Your search keyword '"Shimozaki, Keitaro"' showing total 109 results

Search Constraints

Start Over You searched for: Author "Shimozaki, Keitaro" Remove constraint Author: "Shimozaki, Keitaro"
109 results on '"Shimozaki, Keitaro"'

Search Results

3. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

5. WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)

6. 5-Fluorouracil plus L-leucovorin and oxaliplatin treatment for esophageal squamous cell carcinoma: A multicenter retrospective study

7. ASO Visual Abstract: Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases

8. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis

9. The effectiveness of palliative care via video telemedicine for patients with advanced cancer: A non-randomized prospective clinical trial

10. The impact of palliative care via video telemedicine: A prospective study

11. A scoring system for selecting nivolumab or irinotecan in the later-line chemotherapy for advanced gastric cancer: A Japanese multicenter retrospective study.

12. Efficacy and safety of trastuzumab deruxtecan and nivolumab as third- or later-line treatment for HER2-positive advanced gastric cancer: A single-institution retrospective study.

13. Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: A randomized clinical trial in third- or further-line treatment of gastric cancer.

16. MO39-4 Efficacy and safety of trifluridine/tipiracil as a salvage-line treatment for patients with advanced gastric cancer

17. P57-2 Retrospective study of second-line FOLFOX versus S1 for advanced biliary tract cancer

18. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis

19. Pre-existing Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor-Related Pneumonitis in Solid Tumors: A Retrospective Analysis.

21. The impact of palliative care via video telemedicine: A prospective study

22. Severe drug eruption after antibiotic administration in patients receiving immune checkpoint inhibitors: A monocentric case series

23. Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study

24. Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer

25. Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

26. Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer.

27. KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer

28. Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018

29. Clinical usefulness of postoperative serum carcinoembryonic antigen in colorectal cancer patients with liver metastases.

30. WJOG13219G: Triplet versus doublet in patients with previously untreated BRAFV600E-mutant metastatic colorectal cancer: A multi-institutional real-world data analysis (BRACELET study).

31. Association of disease progression pattern during third-line chemotherapy with nivolumab with poor prognosis in advanced gastric cancer: A multicenter retrospective study in Japan.

32. Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia.

33. Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer

34. Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer

35. Real-world Concordance in Microsatellite Instability Status Between PCR-based Testing and Next-Generation Sequencing Assay for Solid Tumors

36. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors

37. The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study

39. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis

40. Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors

41. Hyperprogressive disease during nivolumab chemotherapy in metastatic gastric cancer: Multicenter retrospective study in Japan.

42. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data.

43. A case report of severe amoebic pancolitis with wide range of ulcerative lesion

44. A retrospective study of immune-related adverse events in various solid tumors

Catalog

Books, media, physical & digital resources